zipalertinib — Topline data
Late 2026
Taiho expects to obtain top-line results by the end of 2026.Source filing
catalyst calendar
CULLINAN THERAPEUTICS INC · Data as of 2026-11-15
Late 2026
Taiho expects to obtain top-line results by the end of 2026.Source filing
Late 2026
After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026Source filing
Q4 2026
In Q4 2026, the Company plans to share initial data from Part A (single target dose escalation) with a focus on safety and B cell depletion in peripheral blood and tissue, as well as other biomarker data and preliminary clinical activity data.Source filing
Q4 2026
Additional multi-dose regimen data in patients with SLE from the Genrix Bio clinical trial in China expected to be shared in Q4 2026Source filing
December
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in DecemberSource filing
Feb 27
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.Source filing
Dec 12
Session Date: December 12, 2026Source filing
Dec 12
Session Date: December 12, 2026Source filing
Dec 13
Session Date: December 13, 2026Source filing